Abstract:
The disclosure relates to an endothelin receptor antagonist for use in the prevention or treatment of brain metastases in combination with a cytotoxic chemotherapy agent, radiotherapy or both. The endothelin receptor antagonist may for example be bosentan, macitentan or a mixture of bosentan and macitentan.
Abstract:
A method and system of preventing a loss/theft of a surveillance target including a mobile device using a wireless personal area network (PAN) or a wireless local area network (LAN) which can receive, from the mobile device included in the surveillance target via a gateway, location information of the surveillance target generated by using mobile device information for the surveillance target, the mobile device information being collected by a sensor of the mobile device, and signal information communicated between the mobile device and a fixed device, can determine whether there is a loss or theft by comparing surveillance target information and a permission standard, and can provide alert information including the location information of the surveillance target when the loss or theft occurs.
Abstract:
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.
Abstract:
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.
Abstract:
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.
Abstract:
A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 μm.
Abstract:
A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 μm, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, retains the full activity of the active ingredient, and when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an in vivo environment the active ingredient in a controlled manner over a long period.
Abstract:
Provided is a method to provide a medical service in a hospital based on Radio Frequency Identification (RFID). The method includes the steps of: a) storing diverse data to provide the service; b) extracting personal identification (ID) using an RFID reader from a RFID tag in a predetermined range; c) receiving requests through an input/output interface; d) searching the requested data among data corresponding to the extracted personal ID; and e) providing the searched data.
Abstract:
A solid lipophilic microparticle having an average particle size ranging from 0.1 to 200 μm, comprising a lipophilic substance, hyaluronic acid or an inorganic salt thereof and an active ingredient selected from the group consisting of a protein or peptide drug, retains the full activity of the active ingredient, and when formulated in the form of an oil dispersion or oil-in-water emulsion, it releases in an in vivo environment the active ingredient in a controlled manner over a long period.
Abstract:
A technique for controlling the developing voltage of an electrophotographic apparatus to accommodate environmental conditions includes: measuring the developing current varying with environmental conditions, and adjusting the high voltage supplied to the developer according to the measured developing current.